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Abstract
Background Possible serologic activity after hepatitis B
surface antigen (HBsAg) seroclearance documented by
conventional assays in chronic hepatitis B (CHB) has not
been thoroughly investigated.
Methods We determined the levels of serum hepatitis B
virus (HBV) DNA, hepatitis B core-related antigen
(HBcrAg), and linearized HBsAg (CLEIA prototype) in
329 CHB patients (72.0% male) after HBsAg seroclearance
was documented by a conventional HBsAg assay.
Results The median interval between presentation and
HBsAg seroclearance was 69.4 months. The median age at
HBsAg seroclearance was 50 years. Assays for serum
HBV DNA, HBcrAg, and linearized HBsAg were per-
formed at a median time interval of 11.2 months after
HBsAg loss. Linearized HBsAg and HBcrAg were
detectable in 85 (25.8%) and 69 (21%) patients, respec-
tively, and one or both serologic markers were detectable
in 133 patients (40.4%). Serum HBV DNA was detectable
in only 7 patients (2.1%). There was no correlation
between linearized HBsAg and HBcrAg levels (r = 0.095,
p = 0.924). The incidences of detectable linearized HBsAg
and HBcrAg did not differ between patient samples taken
at 6–12 and [12 months after HBsAg seroclearance
(p = 0.146 and 0.079, respectively). Among patients with
detectable serologic markers, median levels of linearized
HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not
significantly change with time after HBsAg seroclearance.
Conclusion Using novel HBcrAg and linearized HBsAg
assays, viral serologic activity after HBsAg seroclearance
was demonstrated in more than 40% of CHB patients.
These tests have potential applications in diagnosing and
prognosticating CHB patients with HBsAg seroclearance.
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Introduction
Seroclearance of the hepatitis B surface antigen (HBsAg) is
an uncommon event in the natural history of chronic hep-
atitis B (CHB), with its incidence ranging from 0.1 to
2.26% per year throughout the world [1–3]. Despite being
the ultimate treatment endpoint for CHB, HBsAg sero-
clearance is only seen in 7% of patients after pegylated
interferon therapy [4] and 1.4 to 8%, after long-term
nucleoside analogue therapy [5, 6]. Even after HBsAg
seroclearance, the hepatitis B virus (HBV) is still present at
a low replicative level [7, 8], and patients are still at risk
to the development of hepatocellular carcinoma (HCC)
[9, 10].
An important determinant in the rates of HBsAg
seroclearance would be the sensitivity of the HBsAg assay.
The standard method used currently in commercial assays
is the enzyme-linked immunoassay (ELISA), which has the
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advantage of simplicity. Over the past two decades, there
has been a gradual improvement in the assay’s sensitivity,
with the majority of commercial assays achieving a lower
limit of detection of 0.05 IU/mL [11, 12]. However, the
detection of HBsAg is still not flawless. Conventional
HBsAg assays only target one epitope, i.e., the common
determinant ‘‘a’’; excluding other potential epitopes, which
might lower the assay’s sensitivity [13]. A second factor
determining the assay’s sensitivity would be its capability
in detecting HBsAg mutants [14], in which amino acid
substitution within the ‘‘a’’ determinant could give false
negative results. The development of the hepatitis B core-
related antigen (HBcrAg) assay has resulted in an addi-
tional option in the serologic monitoring of CHB [15].
Based on the simultaneous detection of both hepatitis B e
antigen (HBeAg) and hepatitis B core antigen (HBcAg),
the HBcrAg assay has been shown to correlate well with
serum HBV DNA, intrahepatic HBV DNA, and covalently
closed circular DNA (cccDNA), reflecting actual histologic
severity in CHB [16]. It is not affected by HBeAg status or
the emergence of HBeAg-negative precore mutations [17].
A recent study employed an innovative and highly
sensitive chemiluminescent enzyme immunoassay (CLEIA)
for the quantitative detection of HBsAg (prototype) [18].
Using a combination of monoclonal antibodies, targeting
both the exposed common determinant ‘‘a’’ of the surface
antigen and the epitope embedded inside the lipid bilayer
of the viral envelope, this linearized HBsAg assay is able to
identify HBsAg mutants that evade detection by current
serologic assays [13]. Linearized HBsAg has been shown
to demonstrate good correlation with conventional HBsAg
assays, and in patients receiving nucleoside analogue
therapy, was able to detect HBsAg in the serum after
documented HBsAg seroclearance by conventional assays
[19]. In addition, linearized HBsAg is 10 times more sen-
sitive than current conventional HBsAg assays, with a
lower limit of detection of 0.005 IU/mL. In our current
study, we propose studying the serologic activity of CHB
patients after documented HBsAg seroclearance by a
conventional HBsAg assay using both the HBcrAg and
linearized HBsAg assays.
Methods
In the Department of Medicine, the University of Hong
Kong, Queen Mary Hospital, Hong Kong, all CHB patients
followed up at our clinic underwent tests for serum HBsAg,
antibody to HBsAg (anti-HBs), HBeAg, antibody to
HBeAg (anti-HBe), liver biochemistry, and alpha-fetopro-
tein every 6 months. From September 1990 to April 2010,
we recruited patients who having had documented HBsAg
positivity for at least 6 months were noted to have loss of
serum HBsAg by a conventional HBsAg assay (Abbott
Laboratories, Chicago, IL, USA) at 2 time points at least
6 months apart, with or without the appearance of serum
antibody to HBsAg (anti-HBs). The interval between the
last HBsAg-positive result and HBsAg seroclearance for all
patients was 6 months. All clinical and biochemical data at
initial presentation and during follow-up were recorded.
For patients positive for HBeAg at the initial presentation,
the date of HBeAg seroconversion was recorded.
The conventional HBsAg assay has a lower limit of
detection of 0.05 IU/mL. Anti-HBs, HBeAg, and anti-HBe
were measured using commercially available immuno-
assays (Abbott Laboratories, Chicago, IL, USA). All
patients with concomitant chronic hepatitis C and D, evi-
dence of Wilson disease, autoimmune hepatitis, primary
biliary cirrhosis, and significant intake of alcohol (20 g/day
for women and 30 g/day for men) were excluded. This
study was approved by the Institutional Review Board, the
University of Hong Kong and West Cluster of Hospital
Authority, Hong Kong.
Serum HBV DNA levels, HBcrAg, and linearized
HBsAg were measured at a single time point at least
6 months after HBsAg loss was first documented. Serum
HBV DNA levels were measured by Cobas Taqman assay
(Roche Diagnostics, Branchburg, NJ, USA) with a lower
limit of detection of 20 IU/mL. Serum HBcrAg was mea-
sured using the CLEIA described previously [15, 16].
Briefly, sodium dodecyl sulfate pre-treated serum was
incubated with monoclonal antibodies against denatured
HBcAg and HBeAg. After washing and incubation with
alkaline phosphatase-labeled secondary antibodies, the
relative chemiluminescence intensity was measured, and
the HBcrAg concentration was calculated by comparing
with a standard curve generated using known concentra-
tions of recombinant HBeAg-containing peptides. The cut-
off value of HBcrAg concentration was 1 kU/mL.
Serum linearized HBsAg was measured using an auto-
mated technique based on a CLEIA prototype used in a
previous study by Matsubara et al. [13]. Briefly, serum or
plasma samples with denatured HBsAg were added to
micro-ferrite particles coated with anti-HBs monoclonal
capture antibodies recognizing both the outer epitope
determinant ‘‘a’’ and an inner (normally embedded) epi-
tope. Following incubation and washing, 200 lL substrate
[AMPPD; 3-(20-spiroadamantan)-4-methoxy-4-(30-phos-
phoryloxy) phenyl-1, 2-dioxetane disodium salt] (Applied
Biosystems, Bedford, MA, USA) solution was added and
incubated at 37C for 5 min. The relative intensity of
chemiluminescence was measured, and the HBsAg con-
centration was calculated by comparison with an interna-
tional standard curve. The assay range of HBsAg
concentration in this reagent was 0.005–150 IU/mL, and
retest was acceptable by the 200-fold dilution of sample
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which showed assay range over. In the present study, the
cut-off value of HBsAg concentration was set at 0.005
IU/mL. The entire process was automatically conducted in
Lumipulse G1200 (FujiRebio Inc., Tokyo, Japan).
The differences in the viral components measured by
conventional HBsAg, linearized HBsAg, and HBcrAg
assays are depicted in Fig. 1.
All statistical analyses were performed using SPSS
version 18.0 (SPSS Inc, Chicago, IL, USA). The Kruskal–
Wallis test was used for continuous variables with a
skewed distribution; Chi square test was used for cate-
gorical variables. Correlation between serum linearized
HBsAg, HBcrAg, and other clinical parameters was tested
using Spearman’s bivariate correlation. A two-sided p value
\0.05 was considered statistically significant.
Results
A total of 388 patients referred to our hospital with prior
positive HBsAg result were noted to have HBsAg seroc-
learance using the conventional HBsAg assay during the
recruitment period. By applying the exclusion criteria
mentioned above, the following patients were excluded: no
positive HBsAg result recorded in our center (n = 33),
acute HBV infection (n = 12), subsequent HBsAg rever-
sion (n = 11), documented HBsAg negativity \6 months
(n = 2), and HCV co-infection (n = 1). Three hundred and
twenty-nine patients were eventually recruited for this
study. Their baseline demographics and liver biochemistry
upon presentation are depicted in Table 1. The median
interval between initial presentation, i.e., first documented
date of HBsAg positivity at our clinic, and HBsAg seroc-
learance was 69.4 months (range 6.2–284.2 months).
Forty-seven patients (14.3%) were initially HBeAg-
positive, with HBeAg seroconversion noted after a median
period of 16.3 months (range 1.2–99.6 months). Concern-
ing treatment of CHB, three patients were treated with
conventional interferon-alpha for 52 weeks, with all three
patients achieving HBsAg seroclearance at least 6 years
after completion of interferon therapy. Fourteen patients
(13 on lamivudine and 1 on entecavir) had exposure to
nucleoside analogues. The remaining 312 patients were all
treatment-naı¨ve.
The median age at HBsAg seroclearance was 50 years
(range 4.1–84.7 years), with 48.9% (n = 161) patients
eventually developing anti-HBs, as assessed at the time of
Fig. 1 The difference in viral
components measured by
different serologic assays used
Table 1 Demographics and biochemistry of the studied population at
initial presentation
Number of patients 329
Male (%) 237 (72.0)
Age (years) 42.7 (1.9–79.3)
HBeAg-positive (%) 47 (14.3)
Albumin (g/dL) 45 (29–56)
Bilirubin (lmol/L) 11 (3–132)
ALT (U/L) 33 (4–1522)
Cirrhosis (%) 8 (2.3)
Continuous variables expressed in median (range)
ALT alanine aminotransferase, HBeAg hepatitis B e antigen
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their last follow-up. The median interval between HBsAg
seroclearance and the appearance of anti-HBs was 20.3 months
(range 0–165.7 months). Twelve patients achieved HBsAg
seroclearance after a median therapy duration of 46 months
(range 18–129 months), while two patients achieved HBsAg
loss at 21 and 36 months after the termination of nucleoside
analogues.
Linearized HBsAg, HBcrAg, and HBV DNA levels
were tested at a median interval of 11.2 months (range
6.0–186.9 months) after HBsAg loss was documented by
the conventional HBsAg assay. Sixty-three patients
(19.1%) had detectable anti-HBs during the testing. The
results are depicted in Fig. 2. Eighty-five (25.8%) and
sixty-nine (21%) patients had detectable linearized HBsAg
(range 0.005–150 IU/mL) and HBcrAg (range 1–934
kU/mL), respectively, with detectability of either one or
both viral proteins in 133 patients (40.4%). Twenty-one
patients (6.4%) had both detectable linearized HBsAg and
HBcrAg. The serum tests for linearized HBsAg and
HBcrAg were performed at a median period of 10 (range
6–118) and 11 (range 6–186.9) months after HBsAg se-
roclearance, respectively. Among patients with prior
nucleoside analogue exposure (n = 2) or with nucleoside
analogue therapy at the time of HBsAg seroclearance
(n = 12), six and seven patients had detectable linearized
HBsAg and HBcrAg, respectively. Only seven patients
(2.1%) within the total patient cohort had detectable HBV
DNA (range 20–1,594 IU/mL). Among these seven
patients, five had detectable linearized HBsAg levels, while
none had detectable HBcrAg levels.
Among the 244 patients without detectable linearized
HBsAg, 48 (19.7%) had detectable HBcrAg, with the
median interval of measurement after HBsAg seroclea-
rance being 12 (range 6–136.3) months. There were also
two patients (0.8%) with detectable serum HBV DNA at
6.5 and 42 months after HBsAg seroclearance.
The association of the eventual appearance of anti-HBs
and detectable viral proteins is depicted in Table 2. When
compared to anti-HBs positive patients, a significantly
higher proportion of anti-HBs negative patients had
detectable linearized HBsAg (p \ 0.001). There was no
significant difference in the percentage of patients with
detectable HBcrAg between the two groups (p = 0.949).
Linearized HBsAg levels showed no correlation with
HBcrAg levels (r = 0.095, p = 0.924). Both linearized
HBsAg and HBcrAg levels also showed no correlation with
gender (r = -0.02 and -0.04, p = 0.711 and 0.462,
respectively).
The percentage of patients with detectable linearized
HBsAg and HBcrAg according to the interval between
HBsAg seroclearance and serological testing is shown in
Table 3. The incidences of detectable linearized HBsAg
and HBcrAg did not significantly differ with time after
HBsAg seroclearance at 12, 24, and 36 months (p [ 0.05).
Detectable linearized HBsAg and HBcrAg levels from the
time of HBsAg seroclearance are shown in Fig. 3a and b.
Among patients with detectable serological markers, the
median levels of linearized HBsAg (p = 0.581) and
HBcrAg (p = 0.951) did not change significantly with time
after HBsAg seroclearance.
Discussion
Our present study showed that at least 40% of CHB
patients with documented HBsAg seroclearance using a
conventional HBsAg assay had demonstrable serologic
activity indicative of continuous viral transcription.
Older age is an established predisposing factor for
HBsAg seroclearance [2, 10]. Despite a low annual inci-
dence rate, the cumulative rate of HBsAg seroclearance
after 25 years could reach up to 40% according to a Taiwan
study consisting of 1,965 Chinese CHB patients [20].
Therefore, in an endemic region where the prevalence of
positive antibody to the hepatitis B core antigen (anti-HBc)
Fig. 2 Percentage of patients with detectable viremia and viral
proteins after HBsAg seroclearance documented by a conventional
assay (n = 329). HBsAg hepatitis B surface antigen, anti-HBs
antibody to the hepatitis B surface antigen, HBcrAg hepatitis B
core-related antigen
Table 2 Percentage of patients with detectable serological markers
among patients with and without eventual development of anti-HBs
Anti-HBs positive









24 (14.9%) 61 (36.3%) \0.001
Positive HBcrAg 34 (21.1%) 35 (20.8%) 0.949
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is reported to be between 13.5 and 17% [21–23], it may be
difficult to differentiate CHB patients with HBsAg seroc-
learance and those with prior exposure to HBV, especially
for persons older than 50 years (the median age of HBsAg
loss). Although serum HBV DNA testing is an option for
differentiation, the likelihood of a positive HBV DNA result is
low as shown in our study (2.1%). Even when the lower limit
of detection was improved to 1.1 IU/mL, the chance of HBV
DNA positivity was still only 13.4% [9]. The HBcrAg and
linearized HBsAg assays would be a useful tool in diagnosing
CHB patients with prior HBsAg seroclearance documented by
conventional HBsAg assay before the initial clinical presen-
tation, especially since our present study showed the two viral
proteins could be detected up to 118 and 187 months after
HBsAg seroclearance.
Our present study found that the percentage of detect-
able serologic markers remained similar in serum samples
taken at different time points after HBsAg loss. Moreover,
the median levels of both viral proteins among patients
with detectable markers after HBsAg seroclearance
remained similar over time. Our results suggest that there is
persistent low-grade viral transcriptional activity for years
after HBsAg seroclearance. In addition, the concept of
HBsAg seroclearance might need refinement, given that
25.8% patients with documented HBsAg seroclearance
using a conventional assay had a positive linearized
HBsAg result. However, it should be noted that these
findings are limited by the cross-sectional nature of our
study, with the serum of patients taken at different time
intervals after HBsAg seroclearance. Longitudinal studies
with serial viral protein levels are needed and would be
useful to further investigate the relationship of anti-HBs
with linearized HBsAg.
The pathophysiology of continued viral protein pro-
duction after HBsAg seroclearance is not well-defined. The
presence of viral escape mutants in the ‘‘a’’ determinant is
possible [24]. Although the majority of mutants are
detectable by current serologic assays, detection limits of
HBsAg mutants vary between different assays [25]. HBsAg
production exceeds the required amount for virion assem-
bly of the Dane particle, and can also be secreted as empty
subviral particles [26, 27]. These subviral particles have
been suggested to be involved in the immune evasion
strategy of HBV [28], and could remain in circulation even
when the production of virions decreases [29], as in HBsAg
seroclearance. In CHB patients achieving HBsAg seroc-
learance, intrahepatic cccDNA is still detectable at extre-
mely low levels [9]. Serum HBcrAg levels had been
previously proven to have good correlation with intrahe-
patic cccDNA levels [16]. Despite earlier evidence of good
correlation between serum HBsAg and intrahepatic
cccDNA [30, 31], a recent study did not find such a cor-
relation in HBeAg-negative disease [32], probably since
viral integration, a non-essential event in the life cycle of
HBV, produces HBsAg in the absence of viral replication
[33]. Hence, it is not surprising that studies have shown
that there is no significant HBsAg decline in CHB patients
treated with nucleoside analogues [34]. Further studies are
needed to determine if any correlation exists between lin-
earized HBsAg levels and intrahepatic cccDNA.
Identifying patients with prior HBsAg seroclearance as
documented by a conventional assay carries several clinical
implications. First, an older age at HBsAg seroclearance is
still associated with risk of HCC [9, 10], thus detecting past
HBsAg seroclearance would facilitate the enlisting of such
patients into HCC surveillance programs. Second, fulmin-
ant HBV reactivation is possible in HBsAg-negative but
anti-HBc positive patients undergoing immunosuppres-
sion or chemotherapy, especially for regimens containing
rituximab [35]. Identifying patients with prior HBsAg
Table 3 Percentage of detectable linearized HBsAg and HBcrAg after HBsAg seroclearance
Time from HBsAg seroclearance (months) Linearized HBsAg HBcrAg
Detectable percentage (ratio) p value Detectable percentage (ratio) p value
a: 12 months
B12 29.1% (52/179) 0.146 24.6% (44/179) 0.079
[12 28.2% (33/150) 20.0% (25/125)
b: 24 months
B24 28.4% (71/250) 0.076 20.0% (50/250) 0.441
[24 17.7% (14/79) 24.1% (19/79)
c: 36 months
B36 25.8% (73/283) 0.901 20.1% (57/283) 0.358
[36 26.1% (12/46) 26.1% (12/46)
Patients were divided into two groups for analyses based on the time of measurement after HBsAg seroclearance as documented by a
conventional HBsAg assay: 12 months (a), 24 months (b), and 36 months (c)
HBsAg hepatitis B surface antigen, HBcrAg hepatitis B core-related antigen
102 Hepatol Int (2013) 7:98–105
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seroclearance would allow either preemptive antiviral therapy
or close serologic and virologic monitoring. Third, using both
HBcrAg and linearized HBsAg assays, over 40% of CHB
patients with prior HBsAg seroclearance could be identified.
Detectable HBcrAg and linearized HBsAg in patients con-
sidered to have cryptogenic cirrhosis will reveal the actual
diagnosis to be occult hepatitis B infection. Future studies
could further investigate the relationship of these two novel
serologic markers with both serum anti-HBs and anti-HBc.
There are several limitations of this study, the first being
its cross-sectional nature as mentioned above. HBV genotypes
were not checked in our study. Since genotype-specific
changes were found in HBsAg levels during pegylated
interferon treatment [36], it would be interesting to deter-
mine the effect of genotype on the kinetics of viral protein
production after HBsAg seroclearance. Baseline HBV
DNA levels were not available in our present study. A
previous study in Asian CHB patients found low HBV
DNA levels to be predictive of eventual HBsAg seroclea-
rance [2], and therefore, such data should be included in
future longitudinal studies concerning these two serologic
markers.
Fig. 3 Detectable linearized
HBsAg (a) and HBcrAg
(b) levels after HBsAg
seroclearance as documented by
a conventional HBsAg assay
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In conclusion, the detection of HBcrAg and linearized
HBsAg in more than 40% of CHB patients achieving
HBsAg seroclearance documented by a conventional
HBsAg assay suggests that transcription of viral proteins
still exists even when serum HBsAg is undetectable. These
two novel assays can assist the diagnosis of CHB patients
with prior HBsAg seroclearance. Further longitudinal stud-
ies are needed to determine if these two serologic markers
have prognostic implications for both treated and untreated
CHB patients.
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